LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

Autor:	C. Zhou, Y. Lu, S-W. Kim, T. Baisamut (Reungwetwattana), J. Zhou, Y. Zhang, J. He, J. Yang, Y. Cheng, S-H. Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, T. Xu, V. Archer, M. Hilton, M. Zhou, L. Zhang
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1563
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.10.353
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::337533fb14f97881774ebc719c680a0f https://doi.org/10.1016/j.annonc.2022.10.353 Zobrazit plný text záznamu